Navigation Links
Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
Date:12/5/2013

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24th Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 3:55 p.m. PT/ 12:55 p.m. ET on Wednesday, December 11th, 2013.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Contacts: Marcy Graham

 Ian Stone/David SchullExecutive Director, Investor Relations & Corp Comm 

Media ContactsAmbit Biosciences, Inc.

 Russo Partners858-334-2125

 619-308-6541/212-845-4271mgraham@ambitbio.com

 russopartnersllc.com/david.schull@russopartnersllc.com" rel="nofollow" target="_blank">ian.stone@russopartnersllc.com/david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
2. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
3. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
4. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
5. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
6. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
7. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
8. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
9. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... company of over 2,000 employees and a leader in environmental and life science ... their position as the top American owned and operated environmental testing firm in ... ... ... , enhances Pace Analytical,s capability as an innovative full service provider in ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a leading provider of ... Senior Medical Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate ... Chief Medical Officer of Ambulatory Services for the UVA Health System, brings 30 years ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing homes, ... designed to accommodate patients with a wide range of ailments or special needs, but ... invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many uses, ...
(Date:7/20/2017)... ... 20, 2017 , ... Vixiar Medical, Inc. , a ... for monitoring cardiopulmonary diseases, announced today that it has raised seed round financing ... and fund final engineering and initial production of the Company’s first product, Indicor™, ...
(Date:7/20/2017)... Wisconsin (PRWEB) , ... July 20, 2017 , ... ... of two products that further expand its existing adherence automation lines. The ATP® ... that mirror the advanced technology of TCG’s standard products, but at a size ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):